Patent intelligence · US
US 11472842
Analogues of hepcidin mimetics with improved in vivo half lives
Analogues of hepcidin mimetics with improved in vivo half lives
Patent details — US 11472842
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 18, 2022
- Expiration
- Oct 13, 2042
- Applicant
- Protagonist Therapeutics, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K38/00, A61P, A61P3/02
Quick answer
US 11472842 (Analogues of hepcidin mimetics with improved in vivo half lives) is held by Protagonist Therapeutics, Inc.. Status: granted. Granted Oct 18, 2022. Expires Oct 13, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Protagonist Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K38/00, A61P, A61P3/02
More from Protagonist Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12269856
Hepcidin analogues and uses thereof
granted -
US 12234300
Conjugated hepcidin mimetics
granted -
US 12072338
Pharmaceutical peptides for the treatment of inflammatory diseases
granted -
US 12018057
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
granted -
US 11939361
Compositions of peptide inhibitors of Interleukin-23 receptor
granted -
US 11884748
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
granted -
US 11845808
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
granted -
US 11840581
α4β7 thioether peptide dimer antagonists
granted
Frequently asked questions
What is US patent 11472842?
US 11472842 (Analogues of hepcidin mimetics with improved in vivo half lives) is held by Protagonist Therapeutics, Inc.. Status: granted. Granted Oct 18, 2022. Expires Oct 13, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11472842?
Protagonist Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 33 pharmaceutical patents for this assignee.
When does US 11472842 expire?
Our index shows an expiration date of Oct 13, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.